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Abstract
Nanotherapeutics is a promising field for numerous diseases and represents the forefront of modern medicine. In the present work,
full atomistic computer simulations were applied to study poly(lactic acid) (PLA) nanoparticles conjugated with polyethylene
glycol (PEG). The formation of this complex system was simulated using the reactive polarizable force field (ReaxFF). A full
picture of the morphology, charge and functional group distribution is given. We found that all terminal groups (carboxylic acid,
methoxy and amino) are randomly distributed at the surface of the nanoparticles. The surface design of NPs requires that the
charged groups must surround the surface region for an optimal functionalization/charge distribution, which is a key factor in deter-
mining physicochemical interactions with different biological molecules inside the organism. Another important point that was in-
vestigated was the encapsulation of drugs in these nanocarriers and the prediction of the polymer–drug interactions, which provi-
ded a better insight into structural features that could affect the effectiveness of drug loading. We employed blind docking to predict
NP–drug affinity testing on an antiaggregant compound, cilostazol. The results suggest that the combination of molecular dynam-
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ics ReaxFF simulations and blind docking techniques can be used as an explorative tool prior to experiments, which is useful for
rational design of new drug delivery systems.
Introduction
In recent years, the use of drug delivery systems based on poly-
meric nanoparticles (NPs) has generated innovative therapeutic
strategies for infection and immune diseases, as well as cancer
therapy [1-3]. Polymeric NPs have shown significant advan-
tages compared with many other nanosystems concerning their
biodegradation, biocompatibility and highly modifiable physi-
cal and mechanical properties [1,4-6]. Polymeric materials also
have demonstrated superior efficacy to deliver therapeutic
agents at the site of the disease or damaged area and protecting
drugs against in vitro and in vivo degradation [7-9].
Poly(lactic acid) (PLA) is one of the most commonly used poly-
mers for the synthesis of NPs. PLA is a synthetic biodegradable,
compostable and non-toxic polymer derived from renewable
resources [10-12]. Despite its benefits for different formula-
tions in the medical field [13], the applications of PLA are
limited, mainly due to its weak hydrophilicity and low drug
loading of polar drugs [14]. However, PLA nanoparticles conju-
gated with hydrophilic molecules like poly(ethylene glycol)
(PEG) are a singular kind of functionalized NPs. Several studies
have shown that PEGylation of NPs allows improved blood
circulation, clearance, biocompatibility and less cytotoxicity
[15-19]. Hydrophilic polymer chains at the surface of NPs act
as a steric barrier, reducing the opsonization and the subse-
quent phagocytosis [20-22]. This amphiphilic nature of the
copolymer PLA–PEG supports its high potential for develop-
ment in drug delivery [11] because the PLA core acts as a reser-
voir for hydrophobic drugs while the corona enables a good
dispersion in the blood and offers protection against biological
attack [23,24].
In addition to the hydrophilicity/hydrophobicity ratio, the size
and surface chemistry are crucial factors in NP–cell interac-
tions. Several studies on metallic NPs, carbon nanotubes, and
dendrimers have shown that toxicity of different NPs is deter-
mined by a combination of these factors [25-29]. In this respect,
computational modelling provides useful approaches to help
elucidate the behavior at the atomic level of various nano-
systems, predict their drug affinity, and at the same time, reduce
the number of preliminary experimental tests (or to be used as a
complementary approach to experimental work). The structural
characterization in silico provides a comprehensive under-
standing of properties that govern the formation mechanism and
drug loading of NPs and help create better designs and promis-
ing compositions. Although there are different experimental
methods for synthesis and preparation of PLA–PEG NPs [8,11],
molecular descriptions using computational methodologies still
are not totally addressed.
Wang et al. [30] carried out dissipative particle dynamics
(DPD) simulations to study the PEG–PLA–PEG/paclitaxel
delivery system. The results showed a spherical micelle with the
drug inside and polymer chains distributed on the surface of the
micelle [30]. In a recent investigation [31], it was found that
different computational simulation strategies can successfully
predict the experimental drug affinity and drug loading for
PLA–PEG NPs.
The aim of this work is to characterize at the atomic level the
structural properties of differentially charged polymeric NPs
PEGylated with DSPE–PEG(2000) (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[poly(ethylene glycol)-2000])
carboxylic acid-, methoxy- and amino-terminated NPs prepared
by the nanoprecipitation method and to study the NP–drug com-
plexation for a model antiaggregant compound, cilostazol
[32,33]. PEG chains typically create an interface between the
NP core (PLA) and the hydrophilic environment, where the
drug encapsulation is largely dependent on the intrinsic affinity
between the drug and the PLA core [31]. All-atom molecular
dynamics (MD) simulations were performed using the reactive
force field (ReaxFF) to prove that the self-assembly process of
PLA–PEG NPs is consistent with the experimental method of
synthesis [34], investigate the flexibility of polymer chains, and
characterize the ability to protect a potential cargo. Docking
calculations were employed in order to determine the spatial
distribution of cilostazol in polymeric NPs and to explore its
potential use in this kind of drug delivery system.
Experimental
Characterization of copolymer structures by
all-atom molecular dynamics simulations
The poly(lactic acid) core
PLA polymer chains were built in three-dimensional coordi-
nates with a head-to-tail connection and syndiotactic (D,L) con-
figuration (Figure 1A). The molecular weight distribution of the
polymer that was used in the experiments was not well charac-
terized. Thus, considering the limitations on size and computa-
tional cost of all-atom MD simulations, the length of the PLA
polymer was defined as 20 monomers (Figure 1B).
All MD simulations described in this study were performed
using the molecular dynamics simulator, large-scale atomic/mo-
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Figure 1: Schematic representation of PLA core formation process. Ball and stick representation of A) lactic acid monomer unit and atom definition for
polymeric chain formation, B) poly(D,L-lactic acid) 20 monomer structure and C) van der Waals representation of 10 PLA chains with 20 monomer
units after 2 ns of MD simulation and 20 PLA chains, 40 PLA chains, 80 PLA chains with 20 monomer units after 100 ps of simulation. Snapshots in
time were taken from the MD simulation of PLA core formation with 10 PLA chains. Atoms are colored according to convention (carbon–gray; hydro-
gen–white; oxygen–red) except the head, tail and chiral atoms.
lecular massively parallel simulator (LAMMPS) [35,36]. The
interactions between atomic species were represented with a
novel reactive force field (ReaxFF) [36,37]. This force field
considers both covalent and electrostatic interactions by em-
ploying a bond-order formalism and a polarizable charge de-
scription, enabling depiction of chemical bonding (bond forma-
tion and rupture) without expensive quantum mechanics calcu-
lations [38,39]. In this work, a modified version of the force
field developed by Kim and van Duin, optimized for C/O/H/N/P
systems [40], was used.
The convergence criteria for energy minimization, rupture tem-
perature limit and the optimal separation distance for PLA
chains to build the PLA core were defined as follows.
Stopping tolerance for energy: For a 20-monomer PLA chain,
an energy threshold was defined to perform the energy mini-
mization of the system. The stopping tolerance for energy was
set as 1.0e−12 (means an energy tolerance of one part in 1012).
Rupture temperature limit: With the aim of creating an initial
maximum temperature value (Ti) to be specified at the start of
the equilibration phase, a temperature range from 300 to 600 K
for a 20-monomer PLA chain was evaluated. The Ti was set as
600 K.
Optimal separation distance: To ensure an optimal package
and minimal energetic repulsion between PLA chains,
the optimal separation distance between them was evaluated.
Beilstein J. Nanotechnol. 2018, 9, 1328–1338.
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Figure 3: Molecular structure of DSPE–PEG(2000) carboxy-terminated, methoxy-terminated and amino-terminated formulations.
The separation distance between PLA chains was established in
7 Å (Figure 2). Thus, 10 PLA chains were packed in a
100 × 100 × 100 Å3 periodic box to assemble the PLA core by a
MD simulation in vacuum.
Figure 2: Evaluation of optimal separation distance between PLA
chains. The energy was evaluated for two 20-monomer PLA chains at
3, 4, 5, 6, 7, 8, 9 and 10 Å.
The initially packed configuration was minimized using the
Polak–Ribiere version of the conjugate gradient (CG)
algorithm [41] with a convergence criteria of 1.0e−12 followed
by an equilibration of 2 ns at 310 K using NVT ensemble (con-
stant temperature and volume) and a timestep of 1 fs. A
Nose–Hoover thermostat was used to control the temperature
with a damping of 100 timesteps.
To corroborate the correct assembling methodology, several
MD simulations of 100 ps were performed for 20, 40 and
80 PLA chains (Figure 1C). Data collected along the trajecto-
ries were used to calculate molecular properties such as a radius
of gyration and sphericity with the aim of a better characteriza-
tion of the PLA core shape.
DSPE–PEG coating
Three PLA formulations were analyzed using DSPE–PEG(2000)
carboxylic acid-terminated, methoxy-terminated and amino-
terminated molecules (Figure 3) to provide different surface
charges, which is a critical factor related to toxicity in nano-
systems [25-27,42].
DSPE–PEG structures were built in three-dimensional coordi-
nates. As the starting point, the DSPE–PEG chains were
arranged around the PLA core (10 PLA chains) using
PACKMOL [43,44], as follows.
• The PLA core was fixed with its center of mass at the
center of the system.
• 10 DSPE–PEG configurations were put randomly around
the PLA core with the polar head (P atom of phosphate
group) of these lipids facing the PLA core while the
hydrophilic end (terminal group) of the lipids faced
outwards.
• The P atom, representing the polar head, was con-
strained to be inside a sphere centered at the origin of
radius 40 Å, and the atom representing the terminal
group was constrained to be outside a sphere of radius
140 Å.
Figure 4 shows the built atomistic model and represents the
initial conformation for each case: carboxy-, methoxy- and
amino-terminated PLA nanoparticle.
Then, this starting configuration was also minimized and equili-
brated with the same conditions described above, obtaining the
final PLA–DSPE–PEG-coated structure (Figure 5).
Finally, to analyze the stability of this structure, and at the same
time reduce the computational cost, Langevin dynamics were
performed on these final structures with a friction coefficient of
30 ps−1. In this way, the solvent particles are omitted, and their
effects are represented by a combination of random forces and
frictional terms. Simulations of 1 ns were carried out. The
velocity Verlet-like algorithm was performed at the time of in-
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Figure 4: Schematic representation of the initial structure for DSPE–PEG coating process. The PLA core is represented with spheres using conven-
tional color coding. The center of mass is represented by a yellow sphere at the center of the PLA core. The dotted lines represent the different
boundary areas, such as core–lipid interface (cyan dotted line), polar zone (purple dotted line) and surface charge (orange dotted line). The distance
between the center of mass and the boundary areas is represented using the same color as the dotted lines.
tegration. The temperature was controlled at 310 K with a
Langevin thermostat [45] and the pressure was controlled at
1 atm using a Berendsen barostat [46]. The radius of gyration,
sphericity and molecular distribution of PLA and DSPE–PEG
groups were calculated from the trajectories.
Molecular docking
Blind docking calculations were performed using AutoDock 4.2
[47] software. The 3D structure of the drug (Figure 6A), was
sketched and preoptimized; partial charges were assigned and
rotatable bonds were identified. All files for docking calcula-
tions were prepared using AutoDock tools (ADT) [48]. The ori-
entation of polymer chains obtained from the above MD simu-
lations was used to carry out the docking calculations. Due to
the fact that the polymer core is the protective portion for drugs
in this kind of nanocarrier [31], only the PLA core was consid-
ered for docking calculations.
AutoDock uses a rapid grid-based method for energy evalua-
tion. A grid volume large enough to cover the entire surface of
the PLA core was built (126 × 126 × 126 Å3) using a grid
spacing of 0.5 Å. The grid parameters were generated using
AutoGrid 4.2.6 and the Lamarckian genetic algorithm (LGA)
was used to perform a search of the conformational space of the
drug. The docking runs were set to 100.
The docking poses were analyzed by examining their binding
energy score and the most visited “hot spots” (putative binding
Beilstein J. Nanotechnol. 2018, 9, 1328–1338.
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Figure 5: Snapshots of initial (left) and final (right) conformation of PLA–DSPE–PEG-coated structure after 100 ps of simulation. The PLA core is
represented with conventional color coding (carbon–gray; hydrogen–white; oxygen–red) and the DSPE–PEG chains are coloured green. Lipid chains
fold and cover a significant portion of the PLA core surface.
Figure 6: A) 2D structure of cilostazol. B) Main putative binding sites of cilostazol docked into the PLA core. The PLA core is represented with
conventional color coding and the chains are displayed slightly transparent. Cilostazol poses are represented in sticks.
sites). The most energetically favorable conformations were
selected as the best poses.
Results and Discussion
Poly(lactic acid) core
Radius of gyration
The radius of gyration (Rg) is related to the mean distance of
atoms in a molecular structure with respect to its center of mass
[49]. The radius of gyration is a good indicator of the spatial
conformation of the molecule. Thus, a higher value represents a
higher spatial disposition. The radius of gyration was calcu-
lated for all PLA core models as a function of simulated time,
as shown in Figure 7A.
The mean Rg were calculated, including the last 60 ps of simu-
lation, ensuring a steady value for each PLA core conformation.
For 10 PLA chains, a value of 15.9 ± 0.2 Å was obtained.
Meanwhile, a value of 18.3 ± 0.2 Å, 23.5 ± 0.2 Å and
30.4 ± 0.1 Å was obtained for 20, 40 and 80 PLA chains, re-
spectively.
Triaxial parameter
To identify the grade of spherical shape for the PLA cores of
NPs, a modified script developed by Paz et al. [50] was read-
justed, which classifies the geometrical structures of PLA cores
into three groups of spheroids: spheres, oblates and prolates
[50]. According to the described procedure by Paz et al. [51] to
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Figure 7: A) The radius of gyration and B) triaxial parameter as a function of simulated time for PLA cores with a different number of PLA chains (10,
20, 40 and 80).
analyze the geometric deformations over time, it is necessary to
define the triaxial parameter:
(1)
where a represents the largest axis of symmetry of the spheroid,
b is the middle axis and c is the smallest axis. Based on this,
κ = 0 indicates a sphere, κ > 0 indicates a prolate and κ < 0
denotes an oblate.
Figure 7B shows the evolution of κ vs time for the PLA core
with a different number of PLA chains. The spherical character
increased with a major number of PLA chains. It can be ob-
served that the resulting shape is prolate (κ > 0) for 10, 20 and
40 PLA chains.
The sphericity of PLA cores depends directly on the number of
chains, independent of their initial configuration. In that
context, this behavior is represented by 40 PLA chains (red
line) in Figure 7B, in which the initial configuration (at time 0)
is more prolate compared with 20 PLA chains (pastel blue line),
reaching values of κ = 0.64 and κ = 0.30, respectively. The
initial configuration did not affect the final sphericity of cores
because after only a few nanoseconds, both lines intersected.
The spherical character of PLA cores reached a steady value for
40 and 80 PLA chains after 60 ps of simulation.
DSPE–PEG-coated PLA nanoparticles
Radius of gyration
The radius of gyration can also characterize the relative
DSPE–PEG-coated nanoparticle size and position of the
constituent units. The radius of gyration for differentially
charged (carboxylic acid-, methoxy- and amino-terminated)
DSPE–PEG-coated PLA nanoparticles as a function of time is
shown in Figure 8. For carboxylic acid-, methoxy- and amino-
terminated molecules, the radius of gyration values were
reduced from 62.7 to 20.5, 64.4 to 23.9 and 64.7 to 21.6 Å, re-
spectively.
Figure 8: Radius of gyration as a function of time for anionic
(PLA–PEG–COOH), neutral (PLA–PEG–CH3) and cationic
(PLA–PEG–NH2) nanoparticles.
The different spatial distribution of NPs at the start and at the
end of simulation demonstrates the DSPE–PEG-coated process.
The initial stretched DSPE–PEG chains were folded around the
PLA core, covering the polymer surface (Figure 5).
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Figure 9: Distance between terminal groups from DSPE–PEG–lipid and center of mass of the PLA core as a function of time. Distances between
COOH groups from an anionic nanoparticle and the center of mass of the PLA core are represented in ten different red-styled lines. Distances be-
tween CH3 groups from a neutral nanoparticle and the center of mass of the PLA core are represented in ten different green-styled lines. Distances
between NH2 groups from a cationic nanoparticle and the center of mass of the PLA core are represented in ten different blue-styled lines.
Table 1: Interaction energy (kcal/mol) between the PLA core and DSPE–PEG lipid portion.
Nanoparticle Etotal (PE + KE) EvdW EC
PLA–PEG–COOH −685,941.15 −664,536.34 −27,823.22
PLA–PEG–CH3 −681,862.84 −661,500.71 −27,321.55
PLA–PEG–NH2 −681,010.60 −659,315.18 −27,562.75
The mean Rg values were calculated from the last 40 ps of
simulation, where the structure size appeared to stabilize. It was
observed that the size of all those DSPE–PEG-coated PLA
nanoparticles was homogeneous; however, a slightly larger
particle size was found with methoxy-terminated chains
(24.5 ± 0.6 Å versus 20.7 ± 0.2 Å for carboxylic acid-termi-
nated and 21.8 ± 0.3 Å for amino-terminated NPs). Interest-
ingly, those results were consistent with experimental results
measured by dynamic light scattering [34]. Nevertheless, since
an all-atom and reactive force-field model was used, which in-
creased computational cost, a smaller model was built main-
taining the conformation of the whole system. This is the reason
why discrepancies in scale (≈20 Å and ≈200 nm diameter for
computational and experimental results, respectively) were ob-
served.
Distribution of DSPE–PEG terminal groups
To estimate the charge distribution for each NP, the distance be-
tween different terminal groups (COOH for anionic NP, CH3
for neutral and NH2 for cationic NP) and the center of mass of
the PLA core was measured. Figure 9 shows the distribution of
all terminal groups (ten) of each NP along the simulation.
At the start of the simulation, the terminal groups were ob-
served within 120–160 Å from the center of mass for carboxy-,
methoxy- and amino-terminated NPs, which corresponded to
the stretched DSPE–PEG chains stage. The distance decreased
as simulation time increased in all systems. At the end of the
simulations (last 40 ps) the terminal groups were observed at
24.02 ± 5.8, 22.9 ± 6.6 and 24.1 ± 7.1 Å for carboxy-, methoxy-
and amino-terminated NPs, respectively. Based on the final
values of Rg, it can be suggested that all terminal groups are
randomly distributed at the nanoparticle surface. Ensuring a
correct PEGylation process is crucial. The surface design of
NPs requires that the charged groups must surround the surface
region for an optimal functionalization/charge distribution,
which is a key factor in determining physicochemical interac-
tions with different biological molecules inside the organism
[52].
The interaction energies between the polymeric phase (PLA)
and the lipid portion (DSPE–PEG) (Table 1) were similar in all
cases and it is governed by hydrophobic interactions. Despite
that van der Waals energy was similar in all formulations
(−664,536.34, −661,500.71 and −659,315.18 kcal/mol for
carboxy-, methoxy- and amino-terminated NPs, respectively),
the slightly lower energetic contribution (total energy (Etotal),
potential energy (PE) and kinetic energy (KD), and van der
Waals (vdW) energy (EvdW)) obtained in the amino-terminated
NPs could lead to significant differences in the experimental
synthesis, producing particles with a nonuniform size and/or
aggregates.
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Characterization of NP–drug complexes
Docking studies showed that cilostazol was trapped in PLA
chains and could also be found at the interface of PLA and
DSPE–PEG, interacting with both PLA chains and the non-
polar region of the lipids. The high affinity of cilostazol to the
PLA core was consistent with the A log P value (octanol/water
partition coefficient) of 3.38 calculated using ALOGPS 2.1 soft-
ware package [53] and shown in Table 2. Table 2 and Figure 6B
show the ten lowest energy conformations of cilostazol and
their location within the NP obtained in the docking calcula-
tions.
Table 2: Ten lowest computed binding energy values for cilostazol. An
A log P value of 3.38 was calculated.
Binding energy (kcal/mol)
−6.90
−6.59
−6.59
−6.53
−6.38
−6.24
−6.17
−6.15
−6.13
−6.09
This NP–drug noncovalent complex was established mainly by
hydrophobic interactions, which would allow an easier cargo
delivery as the polymer degrades.
It is important to note that this combined computational meth-
odology could be particularly effective in cases where potential
drugs have similar hydrophobicity values to achieve a first
approximation to guide the experimental phase. It could be ex-
pected that a drug with a lower degree of hydrophobicity would
be more likely to migrate to the surface of the NP, interacting
with the terminal groups of lipid chains (for example through
electrostatic interactions) or with the solvent, and thus, the
protective function of the nanocarrier would be revoked. How-
ever, significant differences in experimental results (drug
loading) have been reported when testing drugs with compa-
rable hydrophobicity [54], which could be explained by
NP–drug interactions calculated by these predictive tools.
Conclusion
In the present study, MD simulations provided a comprehen-
sive understanding of the factors that contribute to PLA–PEG
nanoparticle formation. To the best of our knowledge, this is the
first time that the reactive force field ReaxFF was used to simu-
late polymer nanoparticle formation.
We have characterized the structure of differentially charged
(anionic, neutral and cationic) polymeric DSPE–PEGylated
nanoparticles. We detected a self-assembling process in which a
core–shell structure is observed with PLA in the core and
DSPE–PEG in the shell; this model is consistent with the nano-
precipitation synthesis method previously used [34]. Methoxy-
terminated NPs showed a slightly larger size compared to
charged particles just as it was observed in the experimental
results, and all terminal groups were distributed at the surface of
the NPs.
The combination of MD-ReaxFF and blind docking techniques
described in this work allowed the investigation of the
antiplatelet drug encapsulation ability of polymeric NPs and can
be used as a prior explorative tool or as a complementary ap-
proach to experiments, which is useful for the rational design of
new drug delivery systems.
In future work, this approximation will be correlated with
maximum drug loading determined experimentally and the
protective role of differentially charged PEG for drug release
process will be studied.
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